CSChang Shu

Chang Shu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chang Shu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Jinhuan Wang

    School of Medicine, Nankai University, 94 Weijin Road, Tianjin, 300071, China.

    4 shared publications
  • Qingguo Li

    Department of Neurosurgery, HuanHu Hospital Affiliated to Tianjin Medical University, Tianjin, China

    2 shared publications
  • Qiong Wang

    Tianjin Cerebral Vascular & Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute, Department of Neurosurgery, Tianjin Huan Hu Hospital, Tianjin 300350, PR China

    2 shared publications
  • Xiaoling Yan

    Department of Pathology, Tianjin Huan Hu Hospital, Tianjin 300350, PR China

    2 shared publications
  • Chuanfen Lei

    Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

    1 shared publication
  • Dan Jiang

    Department of Pathology, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    Income level is associated with differences in primary and secondary stroke prevention in China

    byĀ Huiming Ren, Junrong Ma, Xu Guo, Ruijie Zhang, Liyuan Pu, Tian Zhao, Fangfang Zeng, Chang Shu, Liyuan Han, Yunzhi Wang, et al.

    Introduction: The aim of this study was to assess differences in the effects of income level on the primary and secondary prevention of stroke in the Chinese population.Material and methods: This was a population-based study using data from a China Kadoorie Biobank survey that began in 2004 in 10 geographical regions. Community residents (n = 512,715) aged 30–79 years were recruited. Stroke was determined by the self-reporting of a doctor’s diagnosis, and participants with a high risk of stroke were identified using the model developed in the Prediction for ASCVD Risk in China study.Results: The final numbers of people included in this study were 8,884 with stroke and 218,972 with a high risk of stroke. The participants’ income level was positively associated with high levels of physical activity and the consumption of a healthy diet, but negatively associated with the control of alcohol consumption (all p < 0.05). In addition, positive associations were observed between the control of smoking and the use of antiplatelet and antihypertensive medication for primary prevention (all p < 0.05), but there was a negative association with the control of blood pressure (p < 0.001).Conclusions: Low-income individuals were less likely to control smoking and their diet and use preventive medications, while high-income individuals were less likely to control their alcohol consumption and blood pressure. Moreover, medication use was low for both primary and secondary prevention in high-income individuals.


  • Open Access

    Polymorphism rs531564 in miR-124 Maybe a Positive Factor for Cancer Suppression in Chinese People: A Meta Analysis

    byĀ Xin Du, Chang Shu

    China is a large cancer prone country. The relationship between miR-124 rs531564(C>G) polymorphism and cancer risk was studied about Chinese people, according to a meta analysis, in which a total of 3064 cases and 3865 controls were included. The results showed that miR-124 rs531564(C>G) polymorphism might be a positive cancer suppression factors for majority Chinese people, but it was necessary to complete several large samples studies of various types of cancers.

  • Open Access

    95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study

    byĀ J Wu, Wei Hu, Yijun DU, Qian Zhang, Renpeng Zhou, Qin Zhang, Huiling Qin, Zi Ye, Yimei Xu, Sheng Feng, et al.

    Background: HRS-7535, a novel, oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, has demonstrated no strict food restriction, and has been found to obviously improve glucose tolerance, promote insulin secretion, and reduce food consumption in preclinical studies. This study aimed to assess the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of single and multiple ascending doses (SAD and MAD) of HRS-7535 in healthy subjects. Methods: This was a randomized, double-blind, multi-part, phase 1 trial (NCT05347758). Overtly healthy adults 18-55 yrs were eligible, with the body mass index of 19.0-28.0 kg/m2 and the HbA1c of <6.2%. In the SAD, healthy subjects were randomized (6:2) to receive HRS-7535 (15, 60, and 120 mg) or placebo. In the MAD, healthy subjects were randomized (18:6) to receive daily HRS-7535 (120 mg [30/60/90/120 mg titration scheme]) or matching placebo for 4 wks. Results: 24 subjects participated in SAD and 24 participated in MAD, respectively. Most common treatment-emergent adverse events in both SAD and MAD were nausea and vomiting; all TEAEs were mild in severity. PKs were approximately proportional; In SAD, the median Tmax was 5.98-5.99 h and geometric mean t1/2 was 5.28-9.08 h across the HRS-7535 dosing range. In MAD, the median Tmax was 5.98-10.98 h and geometric mean t1/2 was 6.48-8.42 h on Day 28 across the HRS-7535 dosing range. In MAD, the mean reduction in body weight from baseline on Day 29 was 4.38 kg in subjects with HRS-7535. Conclusion: Both SAD and MAD of HRS-7535 showed acceptable safety profile and favorable PKs/PDs. The obvious reductions in body weight could be observed in healthy subjects. These finding support further clinical exploration of HRS-7535 in patients with metabolic syndromes. Disclosure: J. Wu: None. S. Feng: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. C. Shu: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y. Shen: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y. Fan: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. W. Hu: None. Y. Du: None. Q. Zhang: None. R. Zhou: None. Q. Zhang: None. H. Qin: None. Z. Ye: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y. Xu: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Funding: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

  • Long noncoding RNA KB-1460A1.5 inhibits glioma tumorigenesis via miR-130a-3p/TSC1/mTOR/YY1 feedback loop

    byĀ Lixia Xu, Qiaoli Wu, Hua Yan, Chang Shu, Weijia Fan, Xiaoguang Tong, Qingguo Li


  • Open Access

    Early‑onset colorectal cancer: A distinct entity with unique genetic features

    byĀ Dan Jiang, Chang Shu, Chuanfen Lei, Ying Wan, Linyong Sun

    The aim of the present study was to elucidate the genetic features of early‑onset colorectal cancer (CRC), particularly the genetic mutations that may be regarded as prognostic and/or predictive markers in CRC and other malignancies. In total, 40 patients with non‑polyposis CRC aged 35 or younger were selected. The formalin‑fixed, paraffin‑embedded tumors acquired were subjected to mismatch repair (MMR) protein immunochemical staining and gene analysis with next‑generation sequencing (44 exons, 17 genes; Ion Torrent Sequencing Platform). A total of 11 (27.5%) tumors presented with MMR protein deficiency (dMMR) and 26 (65%) tumors harbored one or more genetic mutations, including K‑RAS proto‑oncogene (35%), phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit alpha (PIK3CA; 20%), B‑Raf proto‑oncogene (5%), erb‑b2 receptor tyrosine kinase 2 (5%), discoidin domain receptor tyrosine kinase 2 (5%), N‑RAS proto‑oncogene (2.5%), KIT proto‑oncogene (2.5%), TSC complex subunit 1 (2.5%), DNA methyltransferase 3 alpha (2.5%) and ABL proto‑oncogene 1 (2.5%). Of the dMMR tumors, 81.8% (9/11) of cases presented with mutations in the tested genes, while only 58.6% (17/29) of the MMR‑proficient (pMMR) tumors presented with these (P=0.158). PI3KCA was frequently mutated in dMMR tumors compared to pMMR tumors (P=0.025). In a subgroup with a family history of CRC, the dMMR status (P<0.001) and PIK3CA genetic mutation status (P=0.01) were more frequently observed compared to the other two groups (with a family history of other cancer types or no malignancy). Almost all patients who had relatives with CRC presented with both dMMR and other genetic mutations, while this was not observed in the patients who had relatives with other types of carcinoma. Certain genetic mutations that are rarely reported in CRC were only identified in those patients with a family history of carcinoma. In conclusion, non‑polyposis CRC in young adults presents as a distinct entity with a unique set of genetic features. However, investigation of more cases in further studies is required to verify the present results.


  • Open Access

    Upregulation of SLAMF3 on human T cells is induced by palmitic acid through the STAT5-PI3K/Akt pathway and features the chronic inflammatory profiles of type 2 diabetes

    byĀ Tong Zhou, Guixia Wang, Yanan Lyu, Lei Wang, Siyao Zuo, Jun Zou, Lin Sun, Wenjie Zhao, Chang Shu, Yong-Guang Yang, et al.

    Metabolic stress-induced low-grade chronic inflammation plays an important role in the development of insulin-resistance and type 2 diabetes (T2D). Emerging evidence highlights the importance of directly elucidating T-cell activation under the obesity-induced metabolic stress condition, as T cells primed under such conditions were found to acquire a unique phenotype and function. Herein, we found a significant upregulation of signaling lymphocytic activation molecule family member 3 (SLAMF3) expression on T cells from T2D patients compared to those of healthy controls. Importantly, SLAMF3 upregulation was associated with an increased ability to produce proinflammatory cytokines. Significantly increased SLAMF3 expression was seen in T2D patient T cells that produce IFN-γ or IL-17 upon short (4-h) stimulation, compared to non-cytokine-producing T cells. In line with this finding, SLAMF3highT cells were significantly more sensitive than SLAMF3lowT cells to TCR stimulation with anti-CD3/CD28 antibodies. Furthermore, treatment with palmitic acid (PA) led to significant upregulation of SLAMF3 on human T cells primed by anti-CD3/CD28 antibodies and on Jurkat cells, a human T-cell line. RNA sequencing revealed strong activation of the PI3K/Akt signaling pathway in T cells that were primed with PA. Further mechanistic studies showed that inhibition of PI3K/Akt signaling, or its upstream mediator STAT5 can prevent PA-induced SLAMF3 upregulation on T cells. These results indicate that SLAMF3 upregulation is associated with T-cell activation and cytokine production in T2D patients, and suggest that elevated saturated fatty acids in T2D patients may induce SLAMF3 upregulation on T cells via activation of the STAT5-PI3K/Akt signaling pathway.


  • Open Access

    Tumor-Induced Mortality in Adult Primary Supratentorial Glioblastoma Multiforme with Different Age Subgroups

    byĀ Chang Shu, Xiaoling Yan, Xuebin Zhang, Qiong Wang, Sen Cao, Jinhuan Wang

    Aim: To assess the independent determinants of tumor-induced mortality in different age subgroups after considering competing risk (CR). Methods: Data were extracted from the SEER database. The independent determinants of tumor-induced mortality were defined by CR analysis and validated by conditional inference trees. A CR nomogram was created based on the proportional subdistribution hazard model. Results: The different age subgroups had their own independent determinants of tumor-induced mortality. Using these variables, a CR nomogram was built with good discrimination and calibration. Conclusion: When conducting population-based cohort studies, a CR analysis is recommended for cancers with short survival and high mortality. A CR nomogram represents the first attempt at a predictive model for quantifying tumor-induced mortality.


  • Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma

    byĀ C. Shu, Q. Wang, X. Yan, J. Wang

    Ependymoma is the third most common pediatric brain tumor and occurs most frequently in the posterior fossa. However, the lack of immortalized cell lines, xenografts, or animal models has significantly hindered the study of pediatric posterior fossa ependymoma (P-PF-EPN) pathogenesis. This prompted us to use clinical big data to study this rare disease.


  • Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma

    byĀ Chang Shu, Qiong Wang, Xiaoling Yan, Jinhuan Wang

    The aim of our study is to build a framework for a better understanding of high-grade glioma (HGG) prognostic-related biomarkers. Whole-genome gene expression microarray was performed to identify differently expressed genes between HGGs and low-grade diffuse gliomas. Several machine learning algorithms were used to filter prognostic-related genes. One hundred ninety-three HGG patients after surgical resection were selected for survival analysis. Immunohistochemistry were performed on these tumor samples to analyze IDH1 mutation status and protein expression of WEE1. qRT-PCR, western blotting, transwell assays, and scratch wound healing assays were performed to evaluate the effect of WEE1 knockdown or overexpression in HGG cells. Three prognostic-related genes (WEE1, IGF2PB3, and EMP3) were demonstrated to separate HGG patients into two different survival subgroups. The area under receiver operating characteristic curve of WEE1 was higher than that of IGF2BP3, EMP3, age, IDH status, 1p/19q status, and MGMT promoter status. WEE1 was an independent covariate compared with IDH status, age, and WHO grade. Knockdown or overexpression of WEE1 can inhibit or promote migration and invasion in U251 and U87 cell lines. WEE1, EMP3, and IGF2BP3 are reliable prognostic-related genes at the mRNA level. WEE1 is an independent prognostic biomarker in survival analysis and has potential diagnostic value for HGG patients. WEE1 can induce HGG cell migration and invasion in vitro.